Zydus Wellness PAT at Rs. 21.47 cr. in Q2FY22
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Acute therapies continue to report strong growth compared to chronic ones.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Subscribe To Our Newsletter & Stay Updated